ArticleBMJ open2026
Performance of active drug safety monitoring and management for pharmacovigilance strengthening in Ethiopia, experience from a multidrug-resistant tuberculosis management program: a cross-sectional study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study aimed to assess the performance of active drug safety monitoring and management (aDSM) in the context of multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) treatment programmes to generate insights that could support potential scale-up efforts to strengthen the pharmacovigilance (PV) system in Ethiopia and beyond.
designA cross-sectional study design was employed. The records of patients with MDR/RR-TB enrolled and treated at selected hospitals during April 2018 through February 2023 were reviewed. Data were collected using a structured data extraction form, and Research electronic Data Capture (REDCap) was used for data entry and management. The data were analysed using SPSS version 25, employing descriptive statistics.
settingThe study was carried out at ten (10) public hospitals in Ethiopia.
participantsA total of 1377 patients with MDR/RR-TB were included from 10 hospitals.
resultsOut of the 1377 patients, the majority (59.3%) were males, and 39.9% were new to anti-TB treatment. Deviations from the schedule or missed safety monitoring and other investigations were observed. No records were available for monitoring adverse events (AEs) in 94 (6.8%) of the patients during their treatment follow-up. Overall, 455 (33.0%) patients experienced at least one AE during the treatment period. A total of 774 AE records were identified, of which 134 (17.3%) and 225 (29.1%) were serious adverse events (SAEs) and adverse events of special interest (AESI), respectively. Only 135 (17.4%) of all identified AEs were reported to the PV Centre, of which 70 (51.9%) and 48 (35.6%) were AESI and SAE, respectively. However, the trend of AE detection and reporting showed improvement over the surveyed aDSM implementation period.
conclusionDespite the implementation of aDSM, AE detection and reporting remained suboptimal in the MDR/RR-TB treatment cohort. Therefore, routine aDSM needs to be strengthened and consistently implemented to improve the national pharmacovigilance system and enhance patient safety monitoring and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.